RBO-0618
/ Rubedo Life Sci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 04, 2022
Rubedo Life Sciences
(BIO 2022)
- "Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies."
CNS Disorders • Fibrosis • Lung Cancer
1 to 1
Of
1
Go to page
1